ClinicalTrials.gg
WithdrawnNCT07604792Updated Oct 15, 2026

FIT-(BCMA+CD19)-CAR-T Cells in Recurrent/Refractory Autoimmune Diseases Patients.

An Early Phase 1 interventional study of FIT-(BCMA+CD19)-CAR-T Cells in Autoimmune Diseases, sponsored by Beijing Boren Hospital. Withdrawn at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Beijing Boren Hospital · Early Phase 1, Interventional, and Treatment

How we know

Why this study was withdrawn
No participants

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Sep 2025, registered May 2026).
Updated Oct 15, 2026Now WithdrawnStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 125 studies in Autoimmune Diseases with a site in China — 72 open to participants now, 78 under way, 7 of them phase 3. Autoimmune Diseases · China.

Enrollment
107th of 113
0 · median 30
Started
2025
with 31 others
Phase 1
57 of 125
40 open now
Registered
119th of 125
by date
Lead sponsor
5 of 125
Beijing Boren Hospital

Among the 125 studies in Autoimmune Diseases with a site in China, this one is the 107th largest by enrollment of the 113 interventional ones that give a count, is one of 32 that started in 2025, is one of 57 in phase 1, and was the 119th registered.

Autoimmune Diseases

804 studies on the registry are indexed under Autoimmune Diseases; 273 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

72 of the 125 studies in Autoimmune Diseases with a site in China are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Autoimmune Diseases with a site in China, or all of them as a file.
02

Study summary

This study is a single-center, open-label, single-dose exploration clinical trial for treating patients with partially relapsed/refractory autoimmune diseases by infusing FIT-(BCMA+CD19)-CAR-T cells after pre-treatment with cleansing therapy.

In this study phase, a traditional "3+3" trial design is employed for dose escalation.

Read the detailed description

This study intends to include some patients with relapsed/refractory autoimmune diseases. The subjects will undergo single infusion of FIT-(BCMA+CD19)-CAR-T cells after undergoing screening, collection of peripheral blood mononuclear cells (PBMC), and pre-treatment with conditioning chemotherapy. Apart from the baseline period, the time points for evaluating the therapeutic efficacy of the subjects after treatment are the 1st、2nd、3rd、6th、9th and 12th month after infusion, until disease progression (PD), relapse, change of treatment regimen, death, intolerable toxicity, at the discretion of the investigator, or voluntary withdrawal by the patient (whichever occurs first).

Toxicity will be evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE, version 5.0). Safety of FIT-(BCMA+CD19)-CAR-T cell therapy will be evaluated through laboratory tests, 12-lead electrocardiograms, vital signs, physical examinations, etc. Blood samples will be collected from subjects to assess cellular pharmacokinetics and explore the effects of cellular drugs on ferritin, C-reactive protein, and related cytokines.

03

Conditions studied

  • Autoimmune Diseases

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary participation in the clinical study, with the subject or their legally authorized representative fully understanding and providing written (ICF) for this study, and willingness to comply with and complete all trial procedures.
  2. Aged 18 to 70 years.
  3. performance status ≤ 2.
  4. of at least 12 weeks.
  5. Adequate venous access for apheresis and no other to blood cell separation.
  6. Laboratory parameters at screening must meet the following requirements, with no receipt of cell growth factors within 7 days (or 2 weeks for long-acting formulations) prior to the screening hematology assessment:

    ≥ 1.0 × 10⁹/L. ≥ 60 g/L (without red blood cell transfusion within 14 days). count ≥ 50 × 10⁹/L (thrombocytopenia due to disease may be excluded at the investigator's discretion).

    Absolute lymphocyte count (ALC) ≥ 0.5 × 10⁹/L. Serum total ≤ 1.5 × (ULN). (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN (acute elevations due to autoimmune disease may be excluded at the investigator's discretion).

    (Cockcroft-Gault formula) ≥ 30 mL/min.

  7. Cardiac ≥ 45%, no pericardial effusion (excluding minimal or physiological effusion) confirmed by echocardiography (ECHO), and no findings on (ECG).
  8. Baseline oxygen saturation > 92% while breathing room air.
  9. Female subjects of must have a negative serum or urine pregnancy test (women who have undergone surgical sterilization or have been for at least 2 years are not considered to be of childbearing potential).
  10. Male and female subjects willing to practice from the time of signing the ICF until 12 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Active central nervous system (CNS) disease, such as epilepsy, cerebral ischemia/hemorrhage, dementia, cerebellar disease, or any disease with CNS involvement.
  2. Presence or suspicion of fungal, bacterial (including but not limited to Mycobacterium tuberculosis), viral, or other infection that is uncontrolled or requires intravenous antifungal, antibacterial, or antiviral therapy; uncomplicated urinary tract infection and uncomplicated bacterial pharyngitis are permitted.
  3. (positive for hepatitis B surface antigen [HBsAg] with HBV DNA > 1000 copies/mL), (positive for hepatitis C antibody), syphilis infection (positive for antibody), or (HIV) infection.
  4. Prior or concomitant medication:

    Prior use of any CAR-T cell product or other genetically modified T-cell therapy.

    History of CD19-targeted therapy. Receipt of within 4 weeks before enrollment. Use of another medicinal product within 30 days before screening.

    Receipt of biologic macromolecular drugs (e.g., rituximab, belimumab, telitacicept, adalimumab, etanercept, etc.) that have therapeutic effects on the target indication within 4 weeks or 5 half-lives before enrollment.

    Receipt of > 20 mg/day of prednisone or equivalent doses of other within 2 weeks before enrollment.

    Receipt of conventional synthetic disease-modifying drugs (e.g., cyclophosphamide, methotrexate, leflunomide, sulfasalazine, etc.) that have therapeutic effects on the target indication within 2 weeks before enrollment.

  5. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other cardiac disease within 12 months before enrollment.
  6. History of genetic syndromes associated with bone marrow failure, such as Fanconi anemia, Kostmann syndrome, Schwachman-Diamond syndrome, etc.
  7. History of lymphoproliferative disease or (except for basal cell carcinoma of the skin, in situ carcinoma of the breast/cervix, and other diseases that are disease-free and have not been treated within the past five years).
  8. Women of who are pregnant or breastfeeding.
  9. Any medical activity that may interfere with the evaluation of study safety or efficacy.
  10. In the investigator's judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up, or to comply with the requirements for study participation.

Specific Inclusion/Exclusion Criteria

Systemic Lupus Erythematosus (SLE)

Meet the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for SLE.

Disease activity score (SLEDAI-2000) ≥ 6 and at least one British Isles Lupus Assessment Group (BILAG-2004) category A (severe manifestation) or two category B (moderate manifestation) organ scores, or both; OR SLEDAI-2000 ≥ 8.

Definition of relapsed/refractory: persistent disease activity despite conventional therapy for more than 6 months, or recurrence of disease activity after remission. Conventional therapy is defined as the use of corticosteroids and cyclophosphamide, plus any one or more of the following immunomodulatory drugs: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including rituximab, belimumab, telitacicept, etc.

Relapsed/Refractory Sjögren's Syndrome

Meet the 2002 AECG criteria or the 2016 ACR/EULAR classification criteria for primary Sjögren's syndrome.

Disease activity score (ESSDAI) ≥ 6.

Positive anti-SSA/Ro antibody.

Definition of relapsed/refractory: persistent disease activity despite conventional therapy for more than 6 months, or recurrence of disease activity after remission. Conventional therapy is defined as the use of corticosteroids and cyclophosphamide, plus any one or more of the following immunomodulatory drugs: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including rituximab, belimumab, telitacicept, etc.

Relapsed/Refractory/Progressive Diffuse Scleroderma

Meet the 2013 ACR classification criteria for scleroderma.

Positive scleroderma-associated antibodies.

Diffuse cutaneous sclerosis manifestations or active interstitial lung disease (ground-glass opacities on HRCT).

Definition of relapsed/refractory: persistent disease activity despite conventional therapy for more than 6 months, or recurrence of disease activity after remission. Conventional therapy is defined as the use of corticosteroids and cyclophosphamide, plus any one or more of the following immunomodulatory drugs: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including rituximab, belimumab, telitacicept, etc.

Definition of progressive: rapid skin progression (increase in mRSS > 25%); or progression of lung disease (FVC reduction ≥ 10%, or FVC reduction > 5% accompanied by DLCO reduction ≥ 15%).

Note: Fulfillment of either criterion 4 or criterion 5 is sufficient.

Relapsed/Refractory/Progressive Inflammatory Myopathy

Meet the 2017 EULAR/ACR classification criteria for inflammatory myopathy (including DM, PM, ASS, and NM).

Positive myositis antibodies.

For patients with muscle involvement: MMT-8 score \< 142 and at least two of the following five core set measures are abnormal (PhGA, PtGA, or extra-muscular disease activity score ≥ 2; total HAQ score ≥ 0.25; muscle enzyme levels ≥ 1.5 times the ); OR MMT-8 score ≥ 142 but with active interstitial lung disease (ground-glass opacities on HRCT).

Definition of relapsed/refractory: persistent disease activity despite conventional therapy for more than 6 months, or recurrence of disease activity after remission. Conventional therapy is defined as the use of corticosteroids and cyclophosphamide, plus any one or more of the following immunomodulatory drugs: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including rituximab, belimumab, telitacicept, etc.

Definition of progressive: rapidly progressive interstitial pneumonia within a short period of time.

Note: Fulfillment of either criterion 4 or criterion 5 is sufficient.

Relapsed/Refractory ANCA-Associated Vasculitis

Meet the 2022 ACR/EULAR diagnostic criteria for ANCA-associated vasculitis, including microscopic polyangiitis, granulomatosis with polyangiitis, and eosinophilic granulomatosis with polyangiitis.

Positive ANCA-associated antibodies (MPO-ANCA or PR3-ANCA positive).

Birmingham Vasculitis Activity Score (BVAS) ≥ 15 (total score 63), indicating active vasculitis.

BVAS assessment must include at least one major item, at least three minor items, or at least two renal items (hematuria and proteinuria).

Definition of relapsed/refractory: persistent disease activity despite conventional therapy for more than 6 months, or recurrence of disease activity after remission. Conventional therapy is defined as the use of corticosteroids and cyclophosphamide, plus any one or more of the following immunomodulatory drugs: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including rituximab, belimumab, telitacicept, etc.

Relapsed/Refractory/Catastrophic Antiphospholipid Syndrome

Meet the 2006 Sydney revised diagnostic criteria for primary antiphospholipid syndrome.

Positive medium-to-high titer antiphospholipid antibodies (IgG/IgM of LA, β2GP1, or aCL), with positivity detected more than twice within 12 weeks.

Definition of relapsed/refractory: recurrent thrombosis despite standard treatment with warfarin or alternative vitamin K antagonists (i.e., within therapeutic range) or standard therapeutic dose low molecular weight heparin (LMWH), and prior use of corticosteroids and cyclophosphamide.

Catastrophic antiphospholipid syndrome must meet all four of the following criteria: (1) involvement of three or more organs, systems, and/or tissues; (2) onset of symptoms within one week; (3) histological confirmation of small vessel occlusion in at least one organ or tissue; (4) positive aPL.

Note: Fulfillment of either criterion 3 or criterion 4 is sufficient.

Relapsed/Refractory Autoimmune Hemolytic Anemia

Meet the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Autoimmune Hemolytic Anemia in Adults (2023 Edition).

(i) level meeting the criteria for anemia; (ii) decreased serum haptoglobin (\< 250 mg/L), elevated total (≥ 17.1 μmol/L, predominantly unconjugated bilirubin), elevated lactate dehydrogenase, and reticulocyte percentage > 4% or absolute reticulocyte count > 120 × 10⁹/L; (iii) detection of red blood cell autoantibodies.

Definition of relapsed/refractory: failure, intolerance, or to at least 3 months of therapy with corticosteroids in combination with at least one (cyclophosphamide, azathioprine, vinca alkaloids, calcineurin inhibitors, mycophenolate mofetil) and/or rituximab ( therapy for patients with corticosteroid resistance, relapse, intolerance, dependence, or contraindications: rituximab), with persistent anemia and hemolytic symptoms of varying degrees, and laboratory findings not meeting partial remission criteria (HGB increase > 20 g/L, or HGB normalized but hemolytic biochemical parameters not fully normalized [including reticulocytes, haptoglobin, bilirubin, and lactate dehydrogenase], and transfusion-free for at least 7 days); OR achievement of complete remission (disappearance of clinical symptoms, normalization of red blood cell count, hemoglobin level, reticulocyte percentage, serum bilirubin level, and negative direct and indirect Coombs test) after the above therapy but relapse during maintenance therapy or after drug discontinuation.

Terms in these criteria, in plain language(29)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    FIT-(BCMA+CD19)-CAR-T Cells

    FIT-(BCMA+CD19)-CAR-T cells infusion. Infusion doses: The planned infusion doses are as follows: the first dose group at 1×10\^5 cells/kg; the second dose group at 3×10\^5 cells/kg; the third dose group at 1×10\^6 cells/ kg. Infusion doses refer to the number of CAR-positive cells.

    Biological: FIT-(BCMA+CD19)-CAR-T Cells

Interventions

  • BiologicalFIT-(BCMA+CD19)-CAR-T Cells

    Before cell infusion, researchers may decide, based on necessity, whether to administer prophylactic medication, which may include options such as acetaminophen and diphenhydramine, or H1 antihistamines, among others. Subjects are allowed to receive adequate supportive care after FIT-(BCMA+CD19)-CAR-T cells infusion, including blood transfusions and blood products, antibiotic therapy, antiemetics, antidiarrheals, analgesics, etc.

06

What researchers measure

Primary outcomes

  1. Incidence of dose-limiting toxicity

    The proportion of patients receiving CAR-T cells who encounter dose-limiting toxicities (DLTs). Safety evaluations are performed in accordance with the NCI-CTCAE version 5.0 standards (Cytokine Release Syndrome and neurotoxicity will be graded based on ASTCT/ASBMT grading criteria).

    Time frame: Up to 28 days from CAR-T infusion

07

Study locations

1 site
  • Beijing Gaobo Boren Hospital Co., Ltd
    Beijing, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2025 to primary completion in Nov 2025, 1 month.

Completion moved once since we started tracking on Sep 25, 2026: Nov 2041 → Apr 2026, on Oct 15, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2026
First posted
May 22, 2026
StartActual
Sep 25, 2025
Primary completionActual
Nov 7, 2025
CompletionActual
Apr 30, 2026was Nov 2041
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Withdrawn No participants
changed Oct 15, 2026
Study completion
Nov 30, 2041→Apr 30, 2026 (actual)
Oct 15, 2026
Enrollment
9 (estimated)→0 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Suspended→Withdrawn
    Why stopped No participants
    Study completion Nov 30, 2041→Apr 30, 2026 (now actual)
    Enrollment 9 (estimated)→0 (actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07604792
Lead sponsor
Beijing Boren Hospital
Responsible party
Sponsor
First posted
May 22, 2026
Start date
Sep 25, 2025
Primary completion
Nov 7, 2025
Completion
Apr 30, 2026
Last update
Oct 15, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion